^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RG6440
i
Other names: RG6440, SOF10, RO7496353, RG 6440, RO 7496353, SOF 10, RG-6440, RO-7496353, SOF-10
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
TGF-β1 inhibitor
Related drugs:
5d
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov)
P1, N=102, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
5ms
Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety. (PubMed, Commun Med (Lond))
Selective blockade of latent TGF-β1 activation represents a promising approach for treating a broad range of fibrotic diseases and cancers. By specifically targeting TGF-β1, SOF10 may offer a safer and more effective therapeutic option compared to non-selective TGF-β inhibitors. This strategy has the potential to transform the treatment paradigm for fibrosis-related conditions.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
RG6440
12ms
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov)
P1, N=102, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
over1year
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=120, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Checkpoint inhibition • Metastases
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
3years
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=120, Not yet recruiting, Genentech, Inc.
New P1 trial • Combination therapy • Checkpoint inhibition • Metastases
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
Share via
